◎ Sugi Atlas

Atlas / Disease / Cutaneous lupus erythematosus

Cutaneous lupus erythematosus

disease
On this page

Also known as lupus erythematosus, cutaneous

Summary

Cutaneous lupus erythematosus (MONDO:0005282) is a disease with 11 cohort genes (17 GWAS associations across 5 studies) and 49 clinical trials. Top therapeutic interventions include alitretinoin, anifrolumab, and filgotinib.

At a glance

  • Cohort genes: 11
  • GWAS associations: 17
  • Clinical trials: 49

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namecutaneous lupus erythematosus
Mondo IDMONDO:0005282
EFOEFO:0003834
MeSHD008178
DOIDDOID:0050169
ICD-111401395930
NCITC26819
SNOMED CT7119001
UMLSC0024137
MedGen7401
GARD0006225
Is cancer (heuristic)no

Also known as: lupus erythematosus, cutaneous

Data availability: 17 GWAS associations (5 studies).

Disease family

An umbrella term covering 4 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › connective tissue disorder › rheumatic disorder › lupus erythematosus › cutaneous lupus erythematosus

Related subtypes (2): systemic lupus erythematosus, drug-induced lupus erythematosus

Subtypes (4): subacute cutaneous lupus erythematosus, chronic cutaneous lupus erythematosus, Rowell syndrome, bullous systemic lupus erythematosus

Genetics & variants

GWAS landscape

17 GWAS associations across 5 studies. Top hits map to 9 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs345729439e-37ITGAMG0.63
chr16:312768114e-21G0.76
rs92716426e-20HLA-DRB1 - HLA-DQA1A0.38
rs92675313e-14CSNK2BG2.62
rs31310601e-13HCG20 - LINC00243A2.3
rs1439439474e-13RBM33-DTA2.73
rs1877229451e-12KCNMB2T3.79
rs1133452245e-12RN7SKP167 - FGFR2C1.78
chr6:325732938e-12G0.45
rs5451780951e-11LINC00375 - LINC00351G3.07
rs30940672e-11TRIM39-RPP21, TRIM39G2.32
rs30940842e-11NAPGP2 - MUC21T2.3
rs5343927083e-11SENP6G2.95
rs21876684e-10HLA-DQA1T2.93
rs31305644e-10PSORS1C1T2.05
rs12334918e-10RPS17P1 - LINC02829C2.2

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90476182Verma A2024752450,411Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90476181Verma A2024607121,151Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480452Verma A2024607121,151Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST002884Kunz M20151511,288Genome-wide association study identifies new susceptibility loci for cutaneous lupus erythematosus.
GCST90436600Zhou W2018129401,365Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding0
Tier 2: splice/UTR0
Tier 3: regulatory0
Tier 4: intronic/intergenic16

MAF distribution

BucketVariants
common (>=0.05)11
low_freq (0.01-0.05)0
rare (<0.01)5
unknown0

Functional consequences

ConsequenceCount
intron_variant10
intergenic_variant4
unknown2

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs345729431631261032G>A0.112intron_variantITGAM9e-37Tier 4: intronic/intergenic
chr16:312768110.1044e-21Tier 4: intronic/intergenic
rs9271642632624442A>G,T0.444intergenic_variantHLA-DRB1 - HLA-DQA16e-20Tier 4: intronic/intergenic
rs9267531631668965A>G0.1intron_variantCSNK2B3e-14Tier 4: intronic/intergenic
rs3131060630795514G>A0.112intergenic_variantHCG20 - LINC002431e-13Tier 4: intronic/intergenic
rs1439439477155626886A>C0.001intron_variantRBM33-DT4e-13Tier 4: intronic/intergenic
rs1877229453178502909T>C0.001intron_variantKCNMB21e-12Tier 4: intronic/intergenic
rs11334522410121463848C>T0.001intergenic_variantRN7SKP167 - FGFR25e-12Tier 4: intronic/intergenic
chr6:325732930.3678e-12Tier 4: intronic/intergenic
rs5451780951385209689G>A0.001intron_variantLINC00375 - LINC003511e-11Tier 4: intronic/intergenic
rs3094067630331468T>A,G0.096intron_variantTRIM39-RPP21, TRIM392e-11Tier 4: intronic/intergenic
rs3094084630979732A>C,T0.154intergenic_variantNAPGP2 - MUC212e-11Tier 4: intronic/intergenic
rs534392708675625137G>A,T0intron_variantSENP63e-11Tier 4: intronic/intergenic
rs2187668632638107C>A,G,T0.107intron_variantHLA-DQA14e-10Tier 4: intronic/intergenic
rs3130564631133897C>T0.163intron_variantPSORS1C14e-10Tier 4: intronic/intergenic
rs1233491629493953G>C0.088intron_variantRPS17P1 - LINC028298e-10Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 5 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
CSNK2BOrphanet:178469Autosomal dominant non-syndromic intellectual disability
CSNK2BOrphanet:689397Poirier-Bienvenu neurodevelopmental syndrome
HLA-DQA1Orphanet:391490Adult-onset myasthenia gravis
HLA-DQA1Orphanet:930Idiopathic achalasia
MSH5Orphanet:399805Male infertility with azoospermia or oligozoospermia due to single gene mutation

Cohort genes → proteins

11 cohort genes, 11 distinct canonical proteins.

Evidence partition

SubsetGenes
gwas_only11

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
TRIM39HGNC:10065ENSG00000204599Q9HCM9E3 ubiquitin-protein ligase TRIM39gwas
MAS1LHGNC:13961ENSG00000204687P35410Mas-related G-protein coupled receptor MRGgwas
PSORS1C1HGNC:17202ENSG00000204540Q9UIG5Psoriasis susceptibility 1 candidate gene 1 proteingwas
RPP21HGNC:21300ENSG00000241370Q9H633Ribonuclease P protein subunit p21gwas
MUC21HGNC:21661ENSG00000204544Q5SSG8Mucin-21gwas
CSNK2BHGNC:2460ENSG00000204435P67870Casein kinase II subunit betagwas
FLOT1HGNC:3757ENSG00000137312O75955Flotillin-1gwas
HLA-DQA1HGNC:4942ENSG00000196735P01909HLA class II histocompatibility antigen, DQ alpha 1 chaingwas
MICAHGNC:7090ENSG00000204520Q29983MHC class I polypeptide-related sequence Agwas
MICBHGNC:7091ENSG00000204516Q29980MHC class I polypeptide-related sequence Bgwas
MSH5HGNC:7328ENSG00000204410O43196MutS protein homolog 5gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
TRIM39E3 ubiquitin-protein ligase TRIM39E3 ubiquitin-protein ligase.
RPP21Ribonuclease P protein subunit p21Component of ribonuclease P, a ribonucleoprotein complex that generates mature tRNA molecules by cleaving their 5’-ends.
CSNK2BCasein kinase II subunit betaRegulatory subunit of casein kinase II/CK2.
FLOT1Flotillin-1May act as a scaffolding protein within caveolar membranes, functionally participating in formation of caveolae or caveolae-like vesicles.
HLA-DQA1HLA class II histocompatibility antigen, DQ alpha 1 chainBinds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells.
MICAMHC class I polypeptide-related sequence AWidely expressed membrane-bound protein which acts as a ligand to stimulate an activating receptor KLRK1/NKG2D, expressed on the surface of essentially all human natural killer (NK), gammadelta T and CD8 alphabeta T-cells.
MICBMHC class I polypeptide-related sequence BWidely expressed membrane-bound protein which acts as a ligand to stimulate an activating receptor KLRK1/NKG2D, expressed on the surface of essentially all human natural killer (NK), gammadelta T and CD8+ alphabeta T-cells.
MSH5MutS protein homolog 5Involved in DNA mismatch repair and meiotic recombination processes.

Protein-family classification

Druggable: 6 · Difficult: 1 · Unknown: 4 · Druggable fraction: 0.55

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Antibody/Immunoglobulin38.0×0.032
Kinase12.5×0.749
GPCR12.2×0.749
Enzyme (other)11.1×0.910
Transcription factor10.8×0.910
Other/Unknown40.7×0.946

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
TRIM39Transcription factornoZnf_B-box, Znf_RING, B30.2/SPRY
MAS1LGPCRyesGPCR_Rhodpsn, GPCR_Rhodpsn_7TM, MRGPCRFAMILY
PSORS1C1Other/UnknownnoSEEK1
RPP21Enzyme (other)yes3.1.26.5Rpr2/Snm1/Rpp21
MUC21Other/UnknownnoTandem-repeating_mucin, Mucin_dom
CSNK2BKinaseyesCasein_kinase_II_reg-sub, Casein_kin_II_reg-sub_N, Casein_kinase_II_beta-like
FLOT1Other/UnknownnoBand_7, Flotillin_fam, Band_7/SPFH_dom_sf
HLA-DQA1Antibody/ImmunoglobulinyesMHC_II_a_N, Ig/MHC_CS, Ig_C1-set
MICAAntibody/ImmunoglobulinyesIg_C1-set, Ig-like_dom, MHC_I-like_Ag-recog
MICBAntibody/ImmunoglobulinyesIg_C1-set, Ig-like_dom, MHC_I-like_Ag-recog
MSH5Other/UnknownnoDNA_mismatch_repair_MutS_C, DNA_mismatch_repair_MutS_core, DNA_mismatch_repair_MutS_clamp

Expression context

Cohort genes with no expression data: 0.

6 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)11
unknown0

Top tissues across cohort

TissueCohort genes
left testis4
right testis3
granulocyte2
gall bladder2
rectum2
lower esophagus mucosa2
monocyte2
primordial germ cell in gonad1
smooth muscle tissue1
testis1
lower esophagus1
muscle layer of sigmoid colon1
esophagus mucosa1
vagina1
skin of leg1
left adrenal gland1
left adrenal gland cortex1
right adrenal gland1
descending thoracic aorta1
left ovary1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
TRIM39134ubiquitousyesgranulocyte, primordial germ cell in gonad, left testis
MAS1L58yessmooth muscle tissue, gall bladder, rectum
PSORS1C1124ubiquitousyesleft testis, right testis, testis
RPP21133ubiquitousmarkermuscle layer of sigmoid colon, lower esophagus mucosa, lower esophagus
MUC21103tissue_specificmarkerlower esophagus mucosa, esophagus mucosa, vagina
CSNK2B134ubiquitousmarkerleft testis, right testis, skin of leg
FLOT1134ubiquitousmarkerright adrenal gland, left adrenal gland, left adrenal gland cortex
HLA-DQA1244broadmarkergall bladder, rectum, monocyte
MICA134ubiquitousmarkerdescending thoracic aorta, left ovary, popliteal artery
MICB133ubiquitousyesgranulocyte, leukocyte, monocyte
MSH5134ubiquitousyesright uterine tube, right testis, left testis

Protein interactions among cohort

Intra-cohort edges: 2.

Hub genes (top 10 by interactor count)

SymbolInteractor count
FLOT12,482
MSH51,572
CSNK2B1,486
TRIM391,214
RPP21778
MUC21588
PSORS1C1376
MAS1L286
MICA214
HLA-DQA1196

Intra-cohort edges

ABSources
MICAMICBintact
RPP21TRIM39string_interaction

Structural data

PDB: 7 · AlphaFold-only: 4 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
HLA-DQA1P0190928
CSNK2BP6787010
MICAQ2998310
TRIM39Q9HCM93
RPP21Q9H6332
FLOT1O759552
MICBQ299802

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
MSH5O4319682.36
MUC21Q5SSG874.30
MAS1LP3541066.76
PSORS1C1Q9UIG555.10

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 58. Enrichment computed across 11 evidence-associated genes (8 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 8 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK1285.5×0.059CSNK2B
WNT mediated activation of DVL1178.4×0.059CSNK2B
Condensation of Prometaphase Chromosomes1129.8×0.059CSNK2B
Receptor Mediated Mitophagy1129.8×0.059CSNK2B
Phosphorylation and nuclear translocation of the CRY:PER:kinase complex1102.0×0.059CSNK2B
Maturation of hRSV A proteins195.2×0.059CSNK2B
Defective GALNT3 causes HFTC189.2×0.059MUC21
Defective GALNT12 causes CRCS1189.2×0.059MUC21
Defective C1GALT1C1 causes TNPS184.0×0.059MUC21
Translocation of ZAP-70 to Immunological synapse179.3×0.059HLA-DQA1
Phosphorylation of CD3 and TCR zeta chains168.0×0.059HLA-DQA1
Synaptic adhesion-like molecules168.0×0.059FLOT1
Co-inhibition by PD-1164.9×0.059HLA-DQA1
Signal transduction by L1164.9×0.059CSNK2B
Termination of O-glycan biosynthesis162.1×0.059MUC21
RIPK1-mediated regulated necrosis157.1×0.059FLOT1
Regulation of necroptotic cell death154.9×0.059FLOT1
Dectin-2 family152.9×0.059MUC21
Synthesis of PC151.0×0.059CSNK2B
tRNA processing144.6×0.062RPP21
Generation of second messenger molecules143.3×0.062HLA-DQA1
Regulation of CDH1 posttranslational processing and trafficking to plasma membrane142.0×0.062CSNK2B
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding137.6×0.064CSNK2B
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known137.6×0.064CSNK2B
Meiosis135.7×0.064MSH5
C-type lectin receptors (CLRs)129.7×0.074MUC21
SPOP-mediated proteasomal degradation of PD-L1(CD274)128.6×0.074CSNK2B
Diseases associated with O-glycosylation of proteins126.9×0.076MUC21
tRNA processing in the nucleus124.6×0.077RPP21
Reproduction123.8×0.077MSH5

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 10 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
gamma-delta T cell activation2421.3×6e-04MICA, MICB
response to heat284.3×0.006MICA, MICB
negative regulation of proteasomal ubiquitin-dependent protein catabolic process280.2×0.006TRIM39, CSNK2B
killing of cells of another organism254.4×0.010MICA, MICB
plasma membrane raft assembly1842.6×0.010FLOT1
positive regulation of cell junction assembly1842.6×0.010FLOT1
immune response to tumor cell1561.7×0.010MICA
immune response-activating cell surface receptor signaling pathway1561.7×0.010MICB
positive regulation of synaptic transmission, dopaminergic1561.7×0.010FLOT1
regulation of neurotransmitter uptake1561.7×0.010FLOT1
symbiont-mediated disruption of host cell PML body1561.7×0.010CSNK2B
immune response314.1×0.010HLA-DQA1, MICA, MICB
negative regulation of defense response to virus by host1421.3×0.011MICB
negative regulation of viral life cycle1421.3×0.011CSNK2B
positive regulation of activin receptor signaling pathway1280.9×0.015CSNK2B
plasma membrane raft organization1280.9×0.015FLOT1
regulation of receptor internalization1240.7×0.016FLOT1
negative regulation of natural killer cell activation1210.7×0.016MICA
adiponectin-activated signaling pathway1210.7×0.016CSNK2B
caveola assembly1210.7×0.016FLOT1
chiasma assembly1187.2×0.016MSH5
endothelial tube morphogenesis1187.2×0.016CSNK2B
adaptive immune response216.9×0.017HLA-DQA1, MICB
regulation of cell cycle G1/S phase transition1153.2×0.018TRIM39
tRNA 5’-leader removal1129.6×0.020RPP21
positive regulation of cell-cell adhesion mediated by cadherin1129.6×0.020FLOT1
T cell mediated cytotoxicity1112.3×0.022MICA
peptide antigen assembly with MHC class II protein complex1105.3×0.023HLA-DQA1
negative regulation of cell-cell adhesion199.1×0.023MUC21
negative regulation of natural killer cell mediated cytotoxicity188.7×0.025MICA

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

12 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

DrugHighest phase
AnifrolumabPhase 3
HydroxychloroquinePhase 3
LitifilimabPhase 3
AlitretinoinPhase 2
DazukibartPhase 2
ErgocalciferolPhase 2
EtanerceptPhase 2
FilgotinibPhase 2
Fumaric AcidPhase 2
MocravimodPhase 2
NiacinamidePhase 2
Tacrolimus AnhydrousPhase 2

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 2 · Undrugged: 9

Druggability breadth: 4 of 11 evidence-associated genes (36%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

SymbolExample approved molecule
CSNK2BPALBOCICLIB

Top cohort targets by molecule count

SymbolMoleculesMax phase
CSNK2B144
FLOT112
TRIM3900
MAS1L00
PSORS1C100
RPP2100
MUC2100
HLA-DQA100
MICA00
MICB00

Drugs targeting cohort genes (top 30)

MoleculeMax phaseTargets in cohort
PALBOCICLIB4CSNK2B
MITOXANTRONE4CSNK2B
QUERCETIN3CSNK2B
ENTOSPLETINIB3CSNK2B
SILMITASERTIB2CSNK2B
FISETIN2CSNK2B
ELLAGIC ACID2CSNK2B
MOLIBRESIB2CSNK2B, FLOT1
CI-10402CSNK2B
LUTEOLIN2CSNK2B
ONVANSERTIB2CSNK2B
BAICALEIN2CSNK2B
CHROMOCARB2CSNK2B
KAEMPFEROL1CSNK2B

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
CSNK2B421Binding:419, Functional:2
FLOT17Binding:7
MAS1L2Binding:2
HLA-DQA12Binding:2
MICA1Binding:1

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
RPP213.1.26.5ribonuclease P

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

SymbolChEMBL assays
CSNK2B421

Pharmacogenomics

Cohort genes with a PharmGKB record: 11; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

14 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

CompoundMax phaseCohort target (bioactivity)
PALBOCICLIB4CSNK2B
MITOXANTRONE4CSNK2B
QUERCETIN3CSNK2B
ENTOSPLETINIB3CSNK2B
SILMITASERTIB2CSNK2B
FISETIN2CSNK2B
ELLAGIC ACID2CSNK2B
MOLIBRESIB2CSNK2B, FLOT1
CI-10402CSNK2B
LUTEOLIN2CSNK2B
ONVANSERTIB2CSNK2B
BAICALEIN2CSNK2B
CHROMOCARB2CSNK2B
KAEMPFEROL1CSNK2B

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)1CSNK2B
BPhased (≥1) drug, not yet approved1FLOT1
CDruggable family + PDB, no drug4RPP21, HLA-DQA1, MICA, MICB
DDruggable family + AlphaFold only, no drug1MAS1L
EDifficult family or no structure, no drug4TRIM39, PSORS1C1, MUC21, MSH5

Undrugged target profiles

9 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
TRIM390—
MAS1L2—
PSORS1C10—
RPP210—
MUC210—
HLA-DQA12—
MICA1—
MICB0—
MSH50—

Clinical trials & evidence

Clinical trials

Clinical trials: 49.

Phase distribution (across all retrieved trials)

PhaseTrials
PHASE214
Not specified14
PHASE113
PHASE35
EARLY_PHASE13

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06015737PHASE3ACTIVE_NOT_RECRUITINGA Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06965244PHASE3NOT_YET_RECRUITINGLenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus Erythematosus
NCT07332481PHASE3RECRUITINGA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07355218PHASE3RECRUITINGA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
NCT00470912PHASE3COMPLETEDSunscreen RV 2457C in Photoinduced CLE
NCT07260877PHASE2RECRUITINGA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
NCT07440537PHASE2NOT_YET_RECRUITINGEvaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study
NCT00317681PHASE2COMPLETEDEfficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE)
NCT00523588PHASE2COMPLETEDTreatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser
NCT01300208PHASE2COMPLETEDTo Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus
NCT01352988PHASE2COMPLETEDEfficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus
NCT01407679PHASE2TERMINATEDEfficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus
NCT01498406PHASE2TERMINATEDVitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus
NCT02656082PHASE2COMPLETEDTargeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus
NCT03134222PHASE2COMPLETEDStudy to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
NCT03260166PHASE2UNKNOWNNicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus
NCT04781816PHASE2COMPLETEDProof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus
NCT05629208PHASE2TERMINATEDStudy of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
NCT05879718PHASE2TERMINATEDA Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.
NCT05411016PHASE1ACTIVE_NOT_RECRUITINGA Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus
NCT07306585PHASE1NOT_YET_RECRUITINGThe Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE
NCT07408908PHASE1NOT_YET_RECRUITINGSafety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants..
NCT07455578PHASE1NOT_YET_RECRUITINGStudy of S-4321 in Participants With an Autoimmune or Immune-mediated Disease
NCT01470313PHASE1TERMINATEDA Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus
NCT01702740PHASE1COMPLETEDA Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus
NCT01845740PHASE1COMPLETEDPhase Ib Study of SC Milatuzumab in SLE
NCT02428309PHASE1TERMINATEDAutologous Polyclonal Tregs for Lupus
NCT02927457PHASE1COMPLETEDSafety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects
NCT03817424PHASE1COMPLETEDA Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren’s Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis
NCT04493541PHASE1COMPLETEDA Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus
NCT04647708PHASE1COMPLETEDStudy of M5049 in CLE and SLE Participants
NCT04809623PHASE1TERMINATEDStudy of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
NCT06661213EARLY_PHASE1ENROLLING_BY_INVITATIONTapinarof for Cutaneous Lupus Erythematosus
NCT07072611EARLY_PHASE1RECRUITINGClinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants
NCT01841619EARLY_PHASE1COMPLETEDIVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus
NCT01510067Not specifiedRECRUITINGPrevalence and Clinical Severity of Cutaneous Lupus Erythematosus
NCT06411106Not specifiedRECRUITINGDeep Phenotyping of Cutaneous Lupus Erythematosus
NCT06927219Not specifiedRECRUITINGResearch Accelerated by You Lupus Registry
NCT00222183Not specifiedWITHDRAWNCutaneous Lupus Erythematosus and Elidel
NCT00420121Not specifiedUNKNOWNEuropean Society of Cutaneous Lupus Erythematosus (EUSCLE)

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
ALITRETINOIN41
ANIFROLUMAB41
FILGOTINIB41
METHOTREXATE41
NIACINAMIDE41
PIMECROLIMUS41
TAPINAROF41
DAZUKIBART31
ENPATORAN23
EDECESERTIB22
AFIMETORAN21
DAXDILIMAB21
DOVRAMILAST21
ECLITASERTIB21
LANRAPLENIB21
MILATUZUMAB21

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 73

This page pulls from 73 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondbsnpdepmapdiamond_similaritydoidefoensemblentrezesm2_similarityfantom5_genefantom5_promotergardgenccgenerifgogtopdbgtopdb_interactiongwasgwas_studyhgncicd11intactinterpromedgenmeshmimmondomondochildmondoparentncitorphanetpatentpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptufeatureumlsuniprot